TrialScientific reports2024

Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study.

Lawrence Reiter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.